Nuvation Bio, Inc.

Fundraising by biopharmaceutical companies surged in 2024 to $86.67bn, up 16.2% from $74.59bn in 2023, according to data collected by Biomedtracker. The good fortune was shared across both public and

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

Early development of CDK2 inhibitors has been beset with tolerability problems, particularly ocular and hematological, but new data for two products suggest that headway is being made for some candida

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from